# Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

> **NCT06454448** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Adebrelimab (SHR-1316)
- Decitabine
- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Adebrelimab;decitabine;

## Key facts

- **NCT ID:** NCT06454448
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-15
- **Primary completion:** 2025-06
- **Final completion:** 2026-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06454448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06454448, "Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06454448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*